Development and validation of multivariable prediction models for adverse COVID-19 outcomes in patients with IBD

Public Deposited
Analytics

Downloadable Content

Download PDF
Request Version for Screen Reader
Creator
  • Sperger, John
    • Affiliation: Gillings School of Global Public Health, Department of Biostatistics
  • Shah, Kushal S.
    • Affiliation: Gillings School of Global Public Health, Department of Biostatistics
  • Lu, Minxin
    • Affiliation: Gillings School of Global Public Health, Department of Biostatistics
  • Zhang, Xian
    • Affiliation: School of Medicine, Department of Pediatrics
  • Ungaro, Ryan C.
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • Brenner, Erica J.
    • Affiliation: School of Medicine, Department of Pediatrics
  • Agrawal, Manasi
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • Colombel, Jean-Frédéric
    • Other Affiliation: Icahn School of Medicine at Mount Sinai
  • Kappelman, Michael D.
    • Affiliation: School of Medicine, Department of Pediatrics
  • Kosorok, Michael R.
    • Affiliation: Gillings School of Global Public Health, Department of Biostatistics
Abstract
  • Objectives Develop an individualised prognostic risk prediction tool for predicting the probability of adverse COVID-19 outcomes in patients with inflammatory bowel disease (IBD). Design and setting This study developed and validated prognostic penalised logistic regression models using reports to the international Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease voluntary registry from March to October 2020. Model development was done using a training data set (85% of cases reported 13 March–15 September 2020), and model validation was conducted using a test data set (the remaining 15% of cases plus all cases reported 16 September–20 October 2020). Participants We included 2709 cases from 59 countries (mean age 41.2 years (SD 18), 50.2% male). All submitted cases after removing duplicates were included. Primary and secondary outcome measures COVID-19 related: (1) Hospitalisation+: composite outcome of hospitalisation, ICU admission, mechanical ventilation or death; (2) Intensive Care Unit+ (ICU+): composite outcome of ICU admission, mechanical ventilation or death; (3) Death. We assessed the resulting models’ discrimination using the area under the curve of the receiver operator characteristic curves and reported the corresponding 95% CIs. Results Of the submitted cases, a total of 633 (24%) were hospitalised, 137 (5%) were admitted to the ICU or intubated and 69 (3%) died. 2009 patients comprised the training set and 700 the test set. The models demonstrated excellent discrimination, with a test set area under the curve (95% CI) of 0.79 (0.75 to 0.83) for Hospitalisation+, 0.88 (0.82 to 0.95) for ICU+ and 0.94 (0.89 to 0.99) for Death. Age, comorbidities, corticosteroid use and male gender were associated with a higher risk of death, while the use of biological therapies was associated with a lower risk. Conclusions Prognostic models can effectively predict who is at higher risk for COVID-19-related adverse outcomes in a population of patients with IBD. A free online risk calculator (https://covidibd.org/covid-19-risk-calculator/) is available for healthcare providers to facilitate discussion of risks due to COVID-19 with patients with IBD.
Date of publication
Keyword
DOI
Identifier
Resource type
  • Article
Rights statement
  • In Copyright
License
  • Attribution-NonCommercial 3.0 United States
Journal title
  • BMJ Open
Journal volume
  • 11
Page start
  • e049740
Language
  • English
Version
  • Publisher
ISSN
  • 2044-6055, 2044-6055

Relations

Parents:

This work has no parents.

In Collection:

Items

Thumbnail Title Date Uploaded Visibility Actions
file details e049740.full.pdf 2021-12-01 Public Download